{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigt2xuaadsnrar3pz4hehdvxexc23o2jz353ruuryp6mgfuhrgupq",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mep5vvbhsaw2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibp4j2s5lt6dhw4eda2ia5gtxof4rc62f557upsdup3olvrhwty2m"
    },
    "mimeType": "image/jpeg",
    "size": 414251
  },
  "path": "/news/2026-02-metastasis-therapy-based-glycan.html",
  "publishedAt": "2026-02-12T18:30:01.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Oncology & Cancer"
  ],
  "textContent": "A research team led by Prof. Kenward Vong, Assistant Professor from the Department of Chemistry at The Hong Kong University of Science and Technology (HKUST) has recently achieved a significant breakthrough by bioengineering a new type of glycan-targeting system known as \"lectin-directed protein aggregation therapy (LPAT).\" Using this technology, they developed a therapy capable of preventing the onset and growth of metastatic breast cancers in mouse models.",
  "title": "Researchers develop metastasis prevention therapy based on glycan targeting"
}